NASDAQ
ICCC

ImmuCell Corporation

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

ImmuCell Corporation Stock Price

Vitals

Today's Low:
$4.832
Today's High:
$4.9035
Open Price:
$4.85
52W Low:
$4.26
52W High:
$8.6
Prev. Close:
$4.85
Volume:
3354

Company Statistics

Market Cap.:
$37.57 million
Book Value:
3.467
Revenue TTM:
$15.69 million
Operating Margin TTM:
-40.77%
Gross Profit TTM:
$7.65 billion
Profit Margin:
-38.36%
Return on Assets TTM:
-8.88%
Return on Equity TTM:
-20.26%

Company Profile

ImmuCell Corporation had its IPO on 1987-04-30 under the ticker symbol ICCC.

The company operates in the Healthcare sector and Biotechnology industry. ImmuCell Corporation has a staff strength of 66 employees.

Stock update

Shares of ImmuCell Corporation opened at $4.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.83 - $4.9, and closed at $4.85.

This is a 0% increase from the previous day's closing price.

A total volume of 3,354 shares were traded at the close of the day’s session.

In the last one week, shares of ImmuCell Corporation have increased by +6.36%.

ImmuCell Corporation's Key Ratios

ImmuCell Corporation has a market cap of $37.57 million, indicating a price to book ratio of 1.5962 and a price to sales ratio of 2.5128.

In the last 12-months ImmuCell Corporation’s revenue was $15.69 million with a gross profit of $7.65 billion and an EBITDA of $-3816836. The EBITDA ratio measures ImmuCell Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ImmuCell Corporation’s operating margin was -40.77% while its return on assets stood at -8.88% with a return of equity of -20.26%.

In Q2, ImmuCell Corporation’s quarterly earnings growth was a negative -63.4% while revenue growth was a negative 8.5%.

ImmuCell Corporation’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.78 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ImmuCell Corporation’s profitability.

ImmuCell Corporation stock is trading at a EV to sales ratio of 2.7337 and a EV to EBITDA ratio of 26.5241. Its price to sales ratio in the trailing 12-months stood at 2.5128.

ImmuCell Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$44.01 million
Total Liabilities
$4.19 million
Operating Cash Flow
$-708412.00
Capital Expenditure
$708488
Dividend Payout Ratio
0%

ImmuCell Corporation ended 2024 with $44.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $44.01 million while shareholder equity stood at $26.86 million.

ImmuCell Corporation ended 2024 with $0 in deferred long-term liabilities, $4.19 million in other current liabilities, 781417.00 in common stock, $-9927266.00 in retained earnings and $95557.00 in goodwill. Its cash balance stood at $1.45 million and cash and short-term investments were $1.45 million. The company’s total short-term debt was $2,142,619 while long-term debt stood at $8.64 million.

ImmuCell Corporation’s total current assets stands at $10.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.52 million compared to accounts payable of $918399.00 and inventory worth $7.54 million.

In 2024, ImmuCell Corporation's operating cash flow was $-708412.00 while its capital expenditure stood at $708488.

Comparatively, ImmuCell Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.85
52-Week High
$8.6
52-Week Low
$4.26
Analyst Target Price
$14

ImmuCell Corporation stock is currently trading at $4.85 per share. It touched a 52-week high of $8.6 and a 52-week low of $8.6. Analysts tracking the stock have a 12-month average target price of $14.

Its 50-day moving average was $5.03 and 200-day moving average was $5.71 The short ratio stood at 0.39 indicating a short percent outstanding of 0%.

Around 2822.6% of the company’s stock are held by insiders while 1357% are held by institutions.

Frequently Asked Questions About ImmuCell Corporation

The stock symbol (also called stock or share ticker) of ImmuCell Corporation is ICCC

The IPO of ImmuCell Corporation took place on 1987-04-30

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$809.15
-30.85
-3.67%
$380.2
0.3
+0.08%
$545.1
-36.35
-6.25%
$66.92
-3.6
-5.1%
RARPS (RARPS)
$1.2
-1.05
-46.67%
$8.39
0.02
+0.18%
$0.04
-0.01
-12.67%
$1838.6
-45.35
-2.41%
$0.5
-0.01
-1.96%
$50.5
-1.54
-2.96%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Address

56 Evergreen Drive, Portland, ME, United States, 04103